Acasti Pharma Free Cash Flow 2014-2024 | GRCE
Acasti Pharma free cash flow from 2014 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Acasti Pharma Annual Free Cash Flow |
| 2024 |
-12.24 |
| 2023 |
-15.93 |
| 2022 |
-17.23 |
| 2021 |
-14.39 |
| 2020 |
-23.27 |
| 2019 |
-25.32 |
| 2018 |
-10.12 |
| 2017 |
-6.65 |
| 2016 |
-5.26 |
| 2015 |
-6.44 |
| 2015 |
|
| 2014 |
-6.53 |
| 2014 |
|
| 2013 |
-2.55 |
| 2013 |
|
| Acasti Pharma Quarterly Free Cash Flow |
| 2024-06-30 |
-3.60 |
| 2024-03-31 |
-12.24 |
| 2023-12-31 |
-10.14 |
| 2023-09-30 |
-8.24 |
| 2023-06-30 |
-6.24 |
| 2023-03-31 |
-15.93 |
| 2022-12-31 |
-12.60 |
| 2022-09-30 |
-8.87 |
| 2022-06-30 |
-5.43 |
| 2022-03-31 |
-17.23 |
| 2021-12-31 |
-14.09 |
| 2021-09-30 |
-9.51 |
| 2021-06-30 |
-3.40 |
| 2021-03-31 |
-14.39 |
| 2020-12-31 |
-12.63 |
| 2020-09-30 |
-8.41 |
| 2020-06-30 |
-4.21 |
| 2020-03-31 |
-23.27 |
| 2019-12-31 |
-20.34 |
| 2019-09-30 |
-12.98 |
| 2019-06-30 |
-6.84 |
| 2019-03-31 |
-25.32 |
| 2018-12-31 |
-17.30 |
| 2018-09-30 |
-9.74 |
| 2018-06-30 |
-4.59 |
| 2018-03-31 |
-10.12 |
| 2017-12-31 |
-6.55 |
| 2017-09-30 |
-3.11 |
| 2017-06-30 |
-1.30 |
| 2017-02-28 |
-6.65 |
| 2016-11-30 |
-4.94 |
| 2016-08-31 |
-3.11 |
| 2016-05-31 |
-1.99 |
| 2016-03-31 |
-5.25 |
| 2016-02-29 |
|
| 2015-12-31 |
-3.85 |
| 2015-09-30 |
-2.64 |
| 2015-06-30 |
-0.87 |
| 2015-03-31 |
-6.44 |
| 2014-12-31 |
-4.12 |
| 2014-09-30 |
-2.19 |
| 2014-06-30 |
-0.45 |
| 2014-03-31 |
-6.53 |
| 2014-02-28 |
|
| 2013-12-31 |
-2.00 |
| 2013-09-30 |
-1.17 |
| 2013-06-30 |
-0.92 |
| 2013-03-31 |
-2.55 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.031B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
